当前位置: X-MOL 学术J. Urol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma.
The Journal of Urology ( IF 5.9 ) Pub Date : 2024-05-30 , DOI: 10.1097/ju.0000000000004030
Andrew Zganjar 1 , Abhinav Khanna 1 , Dan Joyce 1 , Paige Nichols 1 , Cameron Britton 1 , Christine M Lohse 2 , John C Cheville 3 , Sounak Gupta 3 , Aaron M Potretzke 1 , R Houston Thompson 1 , Bradley C Leibovich 1 , Stephen A Boorjian 1 , Vidit Sharma 1
Affiliation  

The AUA guidelines introduced a new risk group stratification system based primarily on tumor stage and grade to guide surveillance for patients treated surgically for localized renal cell carcinoma (RCC). We sought to evaluate the predictive ability of these risk groups using progression-free survival (PFS) and cancer-specific survival (CSS), and to compare their performance to that of our published institutional risk models.

中文翻译:


Mayo Clinic 对局限性肾细胞癌 AUA 风险组的验证。



AUA 指南引入了一种新的风险组分层系统,主要基于肿瘤分期和分级,以指导对接受手术治疗的局限性肾细胞癌 (RCC) 患者进行监测。我们试图使用无进展生存期(PFS)和癌症特异性生存期(CSS)来评估这些风险组的预测能力,并将其表现与我们发布的机构风险模型进行比较。
更新日期:2024-05-30
down
wechat
bug